Clinical Trial Update: Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating metformin to reduce paclitaxel-related neuropathy in breast cancer; the study was terminated and results were posted on 2017-08-17.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• metformin (metformin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-08-17